Epilepsy is a chronic neurological disorder characterized by recurrent seizures. As a prevalent condition affecting over 65 million individuals worldwide, its effective management is a crucial area of interest for healthcare professionals. This article aims to provide an updated overview of the recent advancements in epilepsy management.
Several new antiepileptic drugs (AEDs) have been introduced, offering improved safety profiles and fewer drug interactions. These include Lacosamide, Rufinamide, and Eslicarbazepine. Moreover, Cannabidiol has emerged as a promising adjunctive treatment, particularly for drug-resistant seizures in Lennox-Gastaut syndrome and Dravet syndrome.
Surgical treatments for epilepsy have also seen significant advancements. Minimally invasive techniques such as laser interstitial thermal therapy (LITT) and stereotactic EEG-guided radiofrequency thermocoagulation have shown promising results. These procedures offer the potential for fewer complications and faster recovery times compared to traditional resective surgeries.
Neuromodulation therapies, including Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), and Responsive Neurostimulation (RNS), have been refined and are increasingly being used as adjunctive treatments for drug-resistant epilepsy. These therapies offer a potential therapeutic option for patients who are not candidates for epilepsy surgery.
With the advent of next-generation sequencing technologies, genetic testing has become more accessible and affordable. This has enabled the identification of specific genetic mutations associated with various forms of epilepsy, paving the way for precision medicine in epilepsy management.
In conclusion, the field of epilepsy management has seen significant advancements in recent years. These have resulted in a broader range of treatment options, offering improved efficacy and safety for patients. Healthcare professionals should stay abreast of these advancements to provide the best possible care for their patients with epilepsy.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation